aabb-logo-sm

Top Research Chosen for 2025 AABB Annual Meeting’s Plenary Oral Abstract Session

August 06, 2025

AABB is pleased to announce the research selected for this year’s Plenary Oral Abstract Session at the 2025 AABB Annual Meeting. The session will take place on Sunday, Oct. 26, from 10 to 11:30 a.m. PT in Room 20BC.

Each year, the Plenary Oral Abstract Session highlights the year’s most significant research in blood and biotherapies. Among the hundreds of abstracts reviewed by the AABB Selection of Abstracts Committee, six were selected this year for their scientific excellence and their potential to advance the field.

"This year’s Plenary Oral Abstract Session features bold, practice-shaping research, from new insights into alloimmunization and inflammation to innovations in donor screening, lyophilized products and trauma care,” said Christopher Tormey, MD, chair of the AABB Selection of Abstracts Committee. “It’s always a highlight of the meeting, and this year is no exception. Every attendee should make plans to join this essential session."

The Selection of Abstracts Committee has chosen the following abstracts for this year’s Plenary Oral Abstract Session: 

  • “Activation Modulates Macrophage Polarization and Reduces RBC Alloimmunization in a Transfusion Model,” presented by Rosario Hernandez-Armengol, PhD.
  • “Platelet Cold Storage Alters Platelet Extracellular Vesicle Phenotype, Inducing Pro-Inflammatory Responses in Monocytes,” presented by Kelly Lai.
  • “Transfusion-Transmissible Infection Prevalence in U.S. Blood Donations: Comparison of 3-month Deferrals to Individual Donor Assessment,” presented by Emilya Huseynova, MD, MPH.
  • “Toll-like Receptor 9 on Donor RBCs Enhances Transfusion Induced Alloimmunity in Mice,” presented by Arijita Jash, PhD.
  • "Lyophilized Platelet Extracellular Vesicles Mitigate Intracranial Hemorrhage in a Murine Model of Traumatic Brain Injury by Delivering Hemostatic Proteins and mRNA Cargo," presented by Shibani Pati, MD, PhD.
  • "Spray-dried Plasma: A Multi-center, Prospective, Randomized, Dose-escalation Cohort Safety Clinical Trial," presented by Mark Popovsky, MD.

AABB congratulates the researchers selected for this prestigious session and looks forward to their presentations in San Diego.